These businesses face constant pressures through internal movement such as restructuring or acquisitions and external forces driven by competition, shifts in market focus and emerging technologies. Irrespective of this is the fundamental need for R&D functions to perform ‘good science’ – one of the foundation stones of the business.
Thousands of scientists are employed to conduct this ‘good science’, either internally or through external collaboration. There is, however, a major issue with the amount of applied time actually spent by scientists conducting scientific work. The numbers are alarmingly small as organisational complexity places many demands on time, and thus focus is diluted.
As such, the resulting overall R&D productivity is low. This is particularly concerning at a time when the pharmaceutical industry is faced with patent expirations, increased competition and slowing growth, and the added complication of a shrinking pipeline that is failing to produce new blockbuster drugs.
Get the full article on raising R&D productivity
To find out more about raising R&D productivity, please contact us now.